Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

89.35
+0.27000.30%
Post-market: 89.350.00000.00%19:30 EDT
Volume:382.30K
Turnover:34.29M
Market Cap:4.70B
PE:21.48
High:90.81
Open:89.98
Low:89.04
Close:89.08
52wk High:111.42
52wk Low:61.87
Shares:52.57M
Float Shares:51.78M
Volume Ratio:0.56
T/O Rate:0.74%
Dividend:0.32
Dividend Rate:0.36%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.05
PE(LYR):82.73

Loading ...

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

GlobeNewswire
·
Sep 28

Warrior Met Coal (HCC) Tests Investor Patience As Blue Creek Fuels Undervalued View

Simply Wall St.
·
Sep 25

NYSE Order Imbalance 56938.0 Shares on Sell Side

THOMSON REUTERS
·
Sep 17

RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating

MT Newswires Live
·
Sep 16

WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC

GlobeNewswire
·
Sep 14

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

GlobeNewswire
·
Sep 09

Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Dow Jones
·
Sep 08

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

GlobeNewswire
·
Sep 02

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

GlobeNewswire
·
Sep 02

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 01

Tokio Marine HCC International Acquires UK-Based Direct Commercial

MT Newswires Live
·
Aug 31

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Dow Jones
·
Aug 28

IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed

Stock News
·
Aug 27

Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million

Reuters
·
Aug 26

Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110

THOMSON REUTERS
·
Aug 26

Press Release: Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors

Dow Jones
·
Aug 25

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

GlobeNewswire
·
Aug 25

Press Release: Antengene Announces 2026 Interim Results: Achieves First

Dow Jones
·
Aug 24

Warrior Met Coal Director Stephen D. Williams Sells 4,800 Common Shares Worth $500,304

Reuters
·
Aug 22

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20